Ginkgo Bioworks Holdings, Inc.
DNANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for DNA. That does not mean none is planned.
Get an email about DNA's next catalysts
Track Ginkgo Bioworks Holdings (DNA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.
WebsiteNo drugs found in this phase.
Frequently asked questions
When is Ginkgo Bioworks Holdings, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Ginkgo Bioworks Holdings, Inc. (DNA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DNA biotech catalysts?→
Add DNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ginkgo Bioworks Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.